Biomarker Analysis Services for Obesity
Protheragen offers specialized biomarker analysis services exclusively focused on drug discovery and preclinical development for obesity research. Our comprehensive biomarker panel is designed to provide deep insights into the pathophysiology of obesity, supporting the identification and characterization of molecular targets relevant to therapeutic development. Please note that all our services are strictly limited to preclinical research and drug discovery; we do not offer clinical diagnostic services.
Effective therapeutic intervention for obesity begins with the robust discovery and identification of relevant biomarkers. Protheragen's biomarker discovery services leverage advanced screening technologies and scientific expertise to uncover novel molecular indicators associated with obesity. Our approach encompasses high-throughput screening, literature mining, and experimental validation to ensure the identification of promising candidate biomarkers. These efforts are foundational to the drug development process, enabling the rational selection of targets and monitoring of pharmacodynamic responses in preclinical studies.
Multi Omics: Our multi-omics approach integrates cutting-edge genomics, transcriptomics, proteomics, and metabolomics technologies to provide a comprehensive view of biological systems implicated in obesity. By analyzing DNA, RNA, protein, and metabolite profiles, we are able to identify and characterize biomarkers across multiple biological layers. This holistic strategy facilitates the elucidation of complex disease pathways, including those related to energy homeostasis, inflammation, metabolic regulation, and neuroendocrine signaling, all of which are central to obesity pathogenesis.
Candidate Validation: Protheragen employs rigorous validation strategies to confirm the association of candidate biomarkers with obesity pathophysiology. Our preliminary screening processes involve analytical reproducibility assessments, biological relevance evaluation, and cross-comparison with independent datasets. Promising candidates are prioritized based on criteria such as specificity, sensitivity, biological plausibility, and translational potential for preclinical drug development. This systematic prioritization ensures that only the most relevant biomarkers advance to subsequent stages of assay development.
Diverse Technological Platforms: We offer custom assay development capabilities tailored to the unique requirements of obesity research. Our technological platforms are adaptable, supporting a wide range of analytical methods including immunoassays, mass spectrometry, flow cytometry, molecular diagnostics, and advanced histopathology and imaging. This versatility allows us to address specific biomarker detection needs and optimize assays for sensitivity, throughput, and sample type compatibility.
Immunoassays: We utilize ELISA, chemiluminescent, and multiplex immunoassays for sensitive and specific quantification of protein biomarkers such as cytokines, hormones, and adipokines.
Mass Spectrometry: Our LC-MS/MS platforms enable precise quantification of peptides, proteins, and metabolites relevant to obesity research.
Flow Cytometry: We offer flow cytometric analysis for cell surface and intracellular markers, supporting immune profiling and cellular biomarker studies.
Molecular Diagnostics: Our capabilities include PCR, qPCR, and genotyping assays for nucleic acid-based biomarker detection, including genetic variants associated with obesity.
Histopathology and Imaging: We provide advanced tissue-based analyses, including immunohistochemistry and digital pathology, to localize and quantify biomarkers within biological specimens.
Rigorous Method Validation: All analytical methods undergo a rigorous validation process in accordance with industry guidelines. We assess performance characteristics such as accuracy, precision, specificity, sensitivity, linearity, and reproducibility. Comprehensive quality control measures are implemented throughout the assay lifecycle to ensure consistent and reliable results, supporting robust preclinical research outcomes.
Our platforms are designed for quantitative analysis of biomarker concentrations across a variety of sample types. We provide absolute and relative quantification, enabling detailed pharmacodynamic and mechanistic studies. Data integrity and reproducibility are prioritized through standardized protocols and validated analytical workflows.
Sample Analysis: Protheragen handles a wide array of sample types including plasma, serum, tissue lysates, and cell culture supernatants. Our sample analysis protocols are optimized for each matrix to maximize analytical sensitivity and specificity. Stringent quality control procedures are in place to monitor sample integrity, prevent contamination, and ensure the reliability of analytical results.
High Throughput Capabilities: We employ multiplexed analytical platforms that enable high-throughput biomarker analysis, facilitating the simultaneous quantification of multiple targets from minimal sample volumes. This approach enhances efficiency, conserves valuable preclinical samples, and accelerates the pace of discovery in obesity research.
| Gene Target | Biological Function | Application as a Biomarker |
|---|---|---|
| C-C motif chemokine ligand 2 (CCL2) | C-C motif chemokine ligand 2 (CCL2), also known as monocyte chemoattractant protein-1 (MCP-1), is a small cytokine belonging to the CC chemokine family. CCL2 is primarily produced by monocytes, macrophages, endothelial cells, and fibroblasts in response to inflammatory stimuli. Its principal function is to recruit monocytes, memory T cells, and dendritic cells to sites of tissue injury and infection by binding to its receptor, CCR2. CCL2 plays a key role in the regulation of immune and inflammatory responses, and is involved in processes such as wound healing, angiogenesis, and the pathogenesis of various inflammatory diseases. | CCL2 has been studied as a biomarker for a range of conditions characterized by inflammation and immune activation. Elevated levels of CCL2 in blood, cerebrospinal fluid, or tissue samples have been reported in diseases such as atherosclerosis, rheumatoid arthritis, multiple sclerosis, and certain cancers. Measurement of CCL2 concentrations is utilized in research settings to assess the presence and degree of inflammatory activity, monitor disease progression, and evaluate responses to therapeutic interventions. |
| C-reactive protein (CRP) | C-reactive protein (CRP) is an acute-phase protein predominantly produced by hepatocytes in response to interleukin-6 (IL-6) and other pro-inflammatory cytokines. CRP plays a role in the innate immune system by binding to phosphocholine residues present on the surface of dead or dying cells and certain bacteria. This binding facilitates complement activation via the classical pathway and enhances phagocytosis by macrophages, thereby promoting the clearance of pathogens and cellular debris from the circulation. | CRP is widely utilized as a nonspecific biomarker of inflammation. Its concentration in blood increases rapidly and significantly in response to acute inflammatory stimuli, including infection, tissue injury, and chronic inflammatory conditions. Measurement of CRP levels is commonly employed in clinical settings to aid in the detection and monitoring of inflammatory diseases, to assess the severity of infection, and to evaluate the response to therapeutic interventions. Additionally, elevated CRP levels have been associated with increased risk of cardiovascular events, and high-sensitivity CRP assays are used in cardiovascular risk assessment. |
| ghrelin and obestatin prepropeptide (GHRL) | The ghrelin and obestatin prepropeptide (GHRL) gene encodes a precursor protein that is post-translationally cleaved to produce two distinct peptide hormones: ghrelin and obestatin. Ghrelin is primarily produced in the stomach and acts as an endogenous ligand for the growth hormone secretagogue receptor (GHSR). It stimulates the release of growth hormone from the pituitary gland, increases appetite, promotes adiposity, and regulates energy homeostasis. Ghrelin also has roles in gastrointestinal motility, glucose metabolism, and cardiovascular function. Obestatin, derived from the same precursor, has been reported to exert effects that are often opposite to those of ghrelin, such as reducing food intake and inhibiting gastric motility, although its physiological functions are less clearly defined compared to ghrelin. | Circulating levels of ghrelin, derived from the GHRL gene, have been measured as biomarkers in various clinical and research contexts. These include studies of metabolic disorders such as obesity, cachexia, and anorexia nervosa, where altered ghrelin concentrations have been observed. Ghrelin levels have also been investigated in relation to growth hormone deficiency, gastrointestinal diseases, and certain cardiovascular conditions. Obestatin levels have been explored as potential biomarkers in metabolic and gastrointestinal disorders, although their clinical utility remains less characterized. Measurement of these peptides in plasma or serum is typically performed using immunoassays. |
| glucagon (GCG) | Glucagon (GCG) is a peptide hormone produced primarily by the alpha cells of the pancreatic islets. Its principal biological function is to maintain glucose homeostasis by promoting the increase of blood glucose levels, particularly during fasting or hypoglycemic states. Glucagon acts mainly on the liver, stimulating glycogenolysis (the breakdown of glycogen to glucose) and gluconeogenesis (the synthesis of glucose from non-carbohydrate precursors). It also inhibits glycogen synthesis and promotes lipolysis in adipose tissue. The secretion of glucagon is regulated by blood glucose levels, with secretion increasing as glucose levels fall and decreasing as they rise. | Glucagon is utilized as a biomarker in the assessment of glucose metabolism and pancreatic alpha cell function. Measurement of circulating glucagon levels can aid in the evaluation of disorders such as diabetes mellitus, particularly in distinguishing between different types and in understanding dysregulated glucose homeostasis. It is also used in research and clinical settings to assess the effectiveness of interventions targeting glucose regulation and to monitor conditions characterized by abnormal glucagon secretion, such as glucagonoma or certain forms of hypoglycemia. |
| insulin (INS) | Insulin (INS) is a peptide hormone produced by the beta cells of the pancreatic islets. Its primary biological function is the regulation of glucose homeostasis. Upon elevation of blood glucose levels, insulin is secreted into the bloodstream, where it facilitates the uptake of glucose into muscle and adipose tissues and promotes the storage of glucose as glycogen in the liver. Insulin also inhibits hepatic glucose production, lipolysis, and proteolysis, thereby playing a central role in carbohydrate, lipid, and protein metabolism. | Measurement of insulin levels in blood is commonly used in the clinical assessment of glucose metabolism and pancreatic beta-cell function. Insulin quantification can aid in the evaluation of disorders such as diabetes mellitus, insulinoma, and metabolic syndrome. It is also used in research and clinical settings to assess insulin resistance and to monitor the effectiveness of therapeutic interventions targeting glycemic control. |
| interleukin 1 beta (IL1B) | Interleukin 1 beta (IL1B) is a pro-inflammatory cytokine produced primarily by activated macrophages, monocytes, and dendritic cells. It is synthesized as an inactive precursor (pro-IL-1β) and is cleaved to its active form by caspase-1 within the inflammasome complex. IL1B plays a central role in the regulation of immune and inflammatory responses by inducing the expression of adhesion molecules, chemokines, and other cytokines. It promotes fever by acting on the hypothalamus, stimulates the production of acute phase proteins in the liver, and contributes to the activation and recruitment of leukocytes to sites of infection or injury. IL1B is also involved in various cellular processes such as cell proliferation, differentiation, and apoptosis. | IL1B is measured in biological fluids, such as serum, plasma, or synovial fluid, to assess the presence and extent of inflammation. Elevated levels of IL1B have been associated with a variety of inflammatory and autoimmune diseases, including rheumatoid arthritis, gout, sepsis, and inflammatory bowel disease. It is also studied as a marker of systemic inflammation in infectious diseases and certain cancers. The quantification of IL1B can aid in evaluating disease activity, monitoring therapeutic responses, and investigating the mechanisms underlying inflammatory conditions. |
| interleukin 6 (IL6) | Interleukin 6 (IL6) is a multifunctional cytokine produced by a variety of cell types, including T cells, B cells, macrophages, fibroblasts, endothelial cells, and others. IL6 plays a central role in the regulation of immune responses, inflammation, hematopoiesis, and the acute phase response. It acts through binding to the IL6 receptor (IL6R) and subsequent activation of the JAK/STAT signaling pathway. IL6 stimulates the differentiation of B cells into antibody-producing plasma cells, influences T cell differentiation, and induces the hepatic synthesis of acute-phase proteins such as C-reactive protein (CRP) and serum amyloid A. It also has effects on metabolism, bone homeostasis, and neural development. | IL6 is commonly measured in biological fluids, such as serum or plasma, as an indicator of inflammation. Elevated IL6 concentrations have been observed in a range of conditions characterized by inflammatory or immune activation, including infections, autoimmune diseases, and certain cancers. It is also used in clinical settings to assess disease activity or monitor response to therapy in disorders such as rheumatoid arthritis, sepsis, and COVID-19. Measurement of IL6 levels can provide information about the intensity and progression of inflammatory processes. |
| leptin (LEP) | Leptin (LEP) is a hormone predominantly produced by adipocytes (fat cells). It plays a central role in the regulation of energy balance by acting on the hypothalamus to suppress appetite and increase energy expenditure. Leptin signals the status of body fat stores to the central nervous system, thereby influencing food intake and metabolism. In addition to its effects on appetite regulation, leptin is involved in various physiological processes including reproductive function, immune response modulation, and bone metabolism. The LEP gene encodes the leptin protein, and its expression is primarily regulated by energy intake and adiposity. | Leptin levels in blood are frequently measured as an indicator of adiposity and metabolic status. Elevated circulating leptin concentrations are commonly observed in individuals with obesity and are associated with leptin resistance. Leptin has been utilized as a biomarker in clinical and research settings to assess body fat mass, monitor weight loss or gain, and study metabolic disorders such as obesity, metabolic syndrome, and type 2 diabetes. Additionally, altered leptin levels have been studied in relation to reproductive disorders, cardiovascular diseases, and certain inflammatory conditions. |
| melanocortin 4 receptor (MC4R) | The melanocortin 4 receptor (MC4R) is a G protein-coupled receptor predominantly expressed in the central nervous system, especially within the hypothalamus. It plays a critical role in the regulation of energy homeostasis, appetite, and body weight. Activation of MC4R by its endogenous ligands, such as alpha-melanocyte-stimulating hormone (α-MSH), leads to decreased food intake and increased energy expenditure. MC4R signaling is involved in the modulation of satiety and is a key component of the leptin-melanocortin pathway. Genetic variants in MC4R are associated with monogenic and polygenic forms of obesity. | MC4R is utilized as a genetic biomarker in studies of obesity and metabolic disorders. Mutations and polymorphisms in the MC4R gene are analyzed to assess genetic susceptibility to obesity and related metabolic phenotypes. The presence of specific MC4R variants has been associated with early-onset obesity and altered responses to weight management interventions. MC4R genotyping is applied in research settings to investigate the genetic basis of obesity and to stratify individuals based on their risk profiles. |
| tumor necrosis factor (TNF) | Tumor necrosis factor (TNF) is a pro-inflammatory cytokine primarily produced by activated macrophages, as well as by other immune cells such as T lymphocytes and natural killer cells. TNF plays a central role in the regulation of immune responses, inflammation, and apoptosis. It is involved in the activation of endothelial cells, the recruitment of leukocytes to sites of inflammation, and the induction of other cytokines and adhesion molecules. TNF also contributes to the regulation of cellular proliferation, differentiation, and survival, and can initiate programmed cell death (apoptosis) in certain contexts. Dysregulation of TNF production or signaling has been implicated in the pathogenesis of various inflammatory and autoimmune diseases. | TNF is utilized as a biomarker to assess the presence and severity of inflammatory and immune-mediated conditions. Elevated levels of TNF in biological fluids, such as serum or synovial fluid, have been associated with diseases including rheumatoid arthritis, inflammatory bowel disease, sepsis, and certain infectious diseases. Measurement of TNF concentrations can aid in evaluating disease activity, monitoring therapeutic response, and supporting differential diagnosis in clinical and research settings. |
Explore Research Opportunities with Protheragen. Our biomarker research services are designed to advance the understanding of obesity biology and accelerate drug discovery through preclinical development. We offer a broad range of analytical and exploratory capabilities, leveraging state-of-the-art technologies to identify and characterize research biomarkers relevant to obesity. Please note that all biomarkers discussed herein are considered research targets only; we do not claim any biomarkers as validated or mandatory for any specific application. Our focus is exclusively on preclinical research, and we maintain strict scientific objectivity throughout all projects.
We invite you to connect with Protheragen to discuss collaborative opportunities in exploratory biomarker research for obesity. Our team is committed to scientific partnership and knowledge exchange, with an emphasis on preclinical research and objective, data-driven discovery.
Make Order
Experimental Scheme
Implementation
Conclusion
